BEAM position history
The shares of Beam Therapeutics (BEAM) that FARALLON CAPITAL MANAGEMENT, L.L.C. reported in each quarter’s 13F.
Shares held by quarter
New Add Reduce Exit
- 2021 Q3: 1,717,590 shares, $149M, 0.76% of portfolio
- 2021 Q4: 2,265,045 shares, $181M, 0.96% of portfolio, Add +31.9%
- 2022 Q1: 2,594,387 shares, $149M, 0.79% of portfolio, Add +14.5%
- 2022 Q2: 3,472,271 shares, $134M, 0.83% of portfolio, Add +33.8%
- 2022 Q3: 3,631,271 shares, $173M, 1.0% of portfolio, Add +4.6%
- 2022 Q4: 3,399,921 shares, $133M, 0.87% of portfolio, Reduce −6.4%
- 2023 Q1: 3,431,921 shares, $105M, 0.59% of portfolio, Add +0.9%
- 2023 Q2: 3,441,522 shares, $110M, 0.61% of portfolio, Add +0.3%
- 2023 Q3: 4,481,839 shares, $108M, 0.54% of portfolio, Add +30.2%
- 2023 Q4: 4,105,753 shares, $112M, 0.55% of portfolio, Reduce −8.4%
- 2024 Q1: 9,023,506 shares, $298M, 1.4% of portfolio, Add +119.8%
- 2024 Q2: 7,913,123 shares, $185M, 0.87% of portfolio, Reduce −12.3%
- 2024 Q3: 8,208,123 shares, $201M, 0.98% of portfolio, Add +3.7%
- 2024 Q4: 8,239,123 shares, $204M, 1.0% of portfolio, Add +0.4%
- 2025 Q1: 9,928,111 shares, $194M, 1.1% of portfolio, Add +20.5%
- 2025 Q2: 10,013,111 shares, $170M, 0.73% of portfolio, Add +0.9%
- 2025 Q3: 20,126,222 shares, $488M, 2.0% of portfolio, Add +101.0%
- 2025 Q4: 10,063,111 shares, $279M, 1.3% of portfolio, Reduce −50.0%
- 2026 Q1: 10,134,696 shares, $242M, 1.4% of portfolio, Add +0.7%
- 2026 Q2: 10,236,396 shares, $351M, 1.6% of portfolio, Add +1.0%
| Holdings date | Value | % of holdings | Shares | Filing date | All 13F holders |
|---|